Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Bibliographische Detailangaben

Hauptverfasser:	Pemmaraju, Naveen, Mead, Adam J, Somervaille, Tim C.P, McCloskey, James K, Palandri, Francesca, Koschmieder, Steffen, Lavie, David, Leber, Brian, Yeh, Su-Peng, Gomez-Casares, Maria Teresa, Ammatuna, Emanuele, Shin, Ho-Jin, Kirito, Keita, Jourdan, Eric, Devos, Timothy, Chuah, Hun S, Radinoff, Atanas, Bogdanovic, Andrija, Moskal, Rastislav, Jiang, Qi, Chopra, Avijeet S, Papadopoulos, Elektra, Potluri, Jalaja, Passamonti, Francesco
Format:	Other
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!